Imagine a world where common infections become untreatable, where routine surgeries are fraught with deadly risk. That's the chilling reality antibiotic resistance is pushing us towards, and shockingly, the problem is escalating right here in the UK, despite efforts to curb antibiotic use. New data reveals a dangerous trend: while the NHS has slightly reduced antibiotic prescriptions, a surge in private prescribing is fueling a rise in resistant infections and related deaths, widening the gap between the rich and the poor. This isn't just a distant threat; it's a crisis unfolding in our hospitals and communities right now. Buckle up, because the latest findings are deeply concerning.
The UK Health Security Agency (UKHSA) recently released its English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report for 2024-2025. The report paints a worrying picture, showing that despite some progress in reducing overall antibiotic use within the NHS, resistant bacteraemia cases (bloodstream infections) are on the rise, and health inequalities are deepening. You can find the full report here: https://assets.publishing.service.gov.uk/media/69137599d7081798fa18ae0e/ESPAUR-report-2024-2025.pdf.
The numbers don't lie: In 2024, there were 20,484 reported cases of resistant bacteraemia, a significant 9.3% jump from the 18,740 cases reported in 2023. That's nearly 400 new cases of resistant bloodstream infections popping up every week! And the consequences are devastating. Deaths directly linked to these resistant infections climbed from 2041 in 2023 to a staggering 2379 in 2024 – an increase of 16.6%, or 338 lives lost.
Antimicrobial resistance (AMR) is a global threat that experts have been sounding the alarm about for years. Without effective antibiotics, even minor infections can become life-threatening, and commonplace medical procedures – from cesarean sections to hip replacements – could become too dangerous to perform. Think about it: a simple cut could kill you. This is why the rise of AMR is so alarming, and why continued surveillance is crucial. ESPAUR reports have been published annually since 2014, tracking these trends.
E. coli remains the primary culprit behind these resistant bacteraemia cases, accounting for a whopping 65% of infections over the past six years. This highlights the importance of focusing prevention and treatment efforts on this specific pathogen.
This alarming data emerges just one year into the government’s five-year national action plan on AMR (published in May 2024 - https://www.medscape.com/viewarticle/new-uk-5-year-plan-fight-antimicrobial-resistance-2024a10008zs). The plan acknowledges that effective antimicrobials are a “cornerstone” of modern medicine and sets ambitious goals to contain, control, and mitigate AMR by 2040. The UKHSA emphasizes that antibiotic-resistant bacteria are far less responsive to treatment, leading to severe complications like bacteraemia, sepsis, and extended hospital stays. Individuals with resistant infections face a significantly higher risk of death within 30 days compared to those with infections susceptible to antibiotics.
But here's where it gets controversial... While the NHS has made strides in reducing antibiotic prescriptions in primary care (a slight dip from 14.21 to 13.96 daily defined doses per 1000 inhabitants per day (DID) between 2019 and 2024), private antibiotic dispensing in community pharmacies has more than doubled during the same period, soaring from 1.95 to 3.93 DID. This surge in private prescriptions has effectively negated the NHS's efforts, resulting in a 10.7% overall increase in primary care antibiotic use when both NHS and private prescriptions are factored in. In 2024, private prescriptions accounted for a substantial 22% of all dispensed antibiotics. This raises a critical question: is the private healthcare sector undermining public health initiatives aimed at combating antibiotic resistance?
The latest ESPAUR report also incorporates Pharmacy First prescribing data for the first time, revealing that this service accounted for 4% of all primary care antibiotic prescriptions. Tase Oputu, chair of the Royal Pharmaceutical Society England board and a hospital pharmacist with nearly three decades of experience, emphasizes the evidence-based foundation of Pharmacy First, stating that it ensures antibiotics are only provided when clinically appropriate, reinforcing pharmacists' dedication to antimicrobial stewardship. She also anticipates that as more pharmacists gain independent prescribing qualifications, they will play an increasingly important role in managing common conditions, improving access to timely care, and alleviating pressure on the healthcare system.
However, not everyone is convinced that the rise of private prescribing is a positive trend. Dr. Catrin Moore, a Reader and Associate Professor in Global Health and Infectious Diseases at City St George’s, University of London, and co-chair of the Knocking Out AMR Scientific Advisory Group for the Microbiology Society, expressed her concern about the doubling of private dispensing in just one year. She rightly points out that antimicrobial resistance is a pressing healthcare crisis.
And this is the part most people miss... The report highlights a deeply troubling trend: the widening gap in resistant bacteraemia cases between the most and least deprived communities. This inequality gap has ballooned from 29% in 2019 to a shocking 47% in 2024. This means that vulnerable populations are disproportionately affected by antibiotic-resistant infections, exacerbating existing health disparities.
Dr. Moore stresses that this crisis is happening now, right here in the UK, and not just in low- and middle-income countries. She urges immediate action and calls on decision-makers to address the growing health inequalities in the UK. Dr. Jonathan Cox, a Senior Lecturer in Microbiology at Aston University and a member of the advisory group, echoes these concerns, calling the rise in private prescriptions a “significant concern”. He implores colleagues in private practices to consider the long-term consequences of inappropriate prescribing and emphasizes that reducing inappropriate antibiotic consumption and upholding antimicrobial stewardship principles is everyone’s responsibility.
Dr. Cox also calls on the UK government to urgently invest in research and development of novel and alternative antimicrobials and streamline the regulatory process to bring these life-saving treatments to market. The development of new antibiotics has stagnated in recent years, leaving us increasingly vulnerable to resistant infections.
So, what do you think? Is the rise in private antibiotic prescriptions a necessary evil to improve access to care, or a dangerous trend that undermines public health efforts to combat antibiotic resistance? Should the government regulate private prescribing more closely? And how can we ensure that vulnerable communities are not disproportionately affected by this growing crisis? Share your thoughts and opinions in the comments below!
